{"disease":{"id":"visceral-leishmaniasis","name":"Visceral leishmaniasis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"amphotericin-b","indication_name":"Visceral leishmaniasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"miltefosine","indication_name":"Visceral leishmaniasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Impavido","generic_name":"MILTEFOSINE","company_name":"Knight Theraps","drug_phase":"marketed","molecular_target":"RAC-alpha serine/threonine-protein kinase","drug_class":"Antileishmanial [EPC]","quality_score":65,"revenue":null,"mechanism":"Impavido works by inhibiting the RAC-alpha serine/threonine-protein kinase, which is essential for the survival of Leishmania parasites."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00342823","title":"Immunogenetics of Visceral Leishmaniasis","phase":"","overall_status":"COMPLETED","enrollment_count":7000,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT05602610","title":"Clinical Prognostic Score to Predict Relapse in VL","phase":"","overall_status":"RECRUITING","enrollment_count":741,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT05386875","title":"Evaluation to Assess the Usability of rK28 for the Diagnosis of Visceral Leishmaniasis in Kenya","phase":"","overall_status":"UNKNOWN","enrollment_count":625,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT04003532","title":"LAMP Assay for the Diagnosis of Visceral Leishmaniasis","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Prof. Dawit Wolday","has_results":false},{"nct_id":"NCT03129646","title":"Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":439,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":false},{"nct_id":"NCT04342715","title":"A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":216,"lead_sponsor_name":"University of York","has_results":false},{"nct_id":"NCT03269006","title":"Improved Case Detection and Vector Control for Visceral Leishmaniasis","phase":"NA","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","has_results":false},{"nct_id":"NCT07504757","title":"LEISH-PED: Study on Leishmaniasis in Children","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Meyer Children's Hospital IRCCS","has_results":false},{"nct_id":"NCT03636659","title":"Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Aurobindo Pharma Ltd","has_results":false},{"nct_id":"NCT05593666","title":"A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":101,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":false},{"nct_id":"NCT06118749","title":"Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study","phase":"","overall_status":"TERMINATED","enrollment_count":72,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT03929016","title":"Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":false},{"nct_id":"NCT05957978","title":"LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":false},{"nct_id":"NCT05449717","title":"Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan","phase":"","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Epicentre","has_results":false},{"nct_id":"NCT06977490","title":"Human Bioequivalence Study of Amphotericin B Liposome for Injection","phase":"NA","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Sichuan Huiyu Pharmaceutical Co., Ltd","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}